Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.

In 92 people with metastatic renal cell carcinoma, serial Signatera ctDNA negativity or clearance tracked with longer progression-free survival, and longitudinal positivity during surveillance tracked with shorter progression-free survival.

JCO Precision OncologyPubMed 39693589DOI 10.1200/PO-24-00667